shingrixhcp.com
Open in
urlscan Pro
34.107.225.66
Public Scan
Submitted URL: https://www.shingrixhcpupdate.com/
Effective URL: https://shingrixhcp.com/?cc=v_TBKQ7S0D4I445796&mcm=140000
Submission: On March 25 via automatic, source certstream-suspicious — Scanned from DE
Effective URL: https://shingrixhcp.com/?cc=v_TBKQ7S0D4I445796&mcm=140000
Submission: On March 25 via automatic, source certstream-suspicious — Scanned from DE
Form analysis
1 forms found in the DOMGET https://ShingrixHCP.com/search-result/
<form itemprop="potentialAction" itemscope="" itemtype="http://schema.org/SearchAction" class="cf-search-box initialized" action="https://ShingrixHCP.com/search-result/" method="get" data-search-suggestion-enabled="" data-search-suggestion-limit="5">
<meta itemprop="target" content="https://ShingrixHCP.com/?_charset_=UTF-8&q={search_term_string}">
<input type="hidden" name="_charset_" value="UTF-8" data-di-id="di-id-925fa5f9-2523402d"><label for="search_0238637596" class="searchBox-label"> <span class="searchBox-title">Search</span> <input itemprop="query-input" type="text" name="q"
id="search_0238637596" maxlength="2048" class="input-medium search-query" data-di-id="#search_0238637596"> </label><button type="submit" class="button" data-di-id="di-id-c95591a4-5e280d19"> . </button>
<div class="tooltip">
<div class="arrow"></div>
<div class="tooltip-inner"> Tell us what you are looking for in the search box. </div>
</div><input name=":cq_csrf_token" type="hidden" value="undefined" data-di-id="di-id-fd400cd0-4c7c2200">
</form>
Text Content
You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK, and GSK is not responsible for the content provided on that site. Yes No Skip to main content You are using an unsupported browser. Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. Timeout As of January 2023: Some patients have had their co-pays change as a result of the Inflation Reduction Act. Learn More. For US HCPs For US Healthcare Professionals * Patient Populations * 50 years and older * Immunocompromised, 18 years and older * Prescribing Info * Patient Populations * 50 years and older * Immunocompromised, 18 years and older * Prescribing Information * GSK MedInfo * Visit US Patient Site * Order SHINGRIX Menu Search . Tell us what you are looking for in the search box. Search * CDC Recommendations * Who To Vaccinate * Who To Vaccinate Overview * Shingles & Aging * Patient Profiles * Efficacy & Safety * Efficacy & Safety Overview * Efficacy Data * Safety Profile * Mechanism of Action * In Your Practice * In Your Practice Overview * Patient Counseling * Storage & Dosing * Reconstitution & Administration * Coverage & Coding * Support for Nurses * Resource Library * Resource Library Overview * On-Demand Videos * Resources * Educational Events * GSK MedInfo * Visit US Patient Site * Order SHINGRIX IF YOU COULD PREVENT SHINGLES, WHY WOULDN'T YOU? MAKE VACCINATION A PRIORITY YEAR-ROUND FOR YOUR PATIENTS 50 YEARS AND OLDER1,2 Not an actual patient. Indication: SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox). We make it easy to order the vaccines you need online Order NOW Educational Events Plan ahead. Check the calendar to see the list of upcoming educational events and sign up here. On-Demand Want to brush up on your SHINGRIX knowledge? We offer a range of educational videos on topics that include highlights of the pivotal trials, MOA, and reconstitution. Check out our On-Demand Videos. ARE YOU PROTECTING YOUR PATIENTS 50 YEARS AND OLDER WITH SHINGRIX?1 The actions of you and your team can help prevent shingles in your patients. Use our patient profiles to help identify the types of potential patients for SHINGRIX. See Patient Profiles Learn how to talk to your patients about what to expect, including common adverse reactions. Get Counseling Tips CDC STATES THAT SHINGRIX IS RECOMMENDED FOR THE PREVENTION OF HERPES ZOSTER AND RELATED COMPLICATIONS FOR IMMUNOCOMPETENT ADULTS AGED ≥50 YEARS.3 CDC Recommendations and Important Considerations SHINGRIX is not indicated for prevention of herpes zoster-related complications. CDC=Centers for Disease Control and Prevention. YOU MAY ALSO BE INTERESTED IN: Storage & Dosing Learn how to store SHINGRIX and about the importance of proper dosing. Coverage & Coding Get product coding and coverage details for commercial medical benefit and Medicare Part D insurance. Safety Profile See the safety results from 2 phase 3 clinical studies in adults 50 years and older. Expand/Collapse Indication & Important Safety Info Indication SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles): * in adults aged 50 years and older. * in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox). Important Safety Information * SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX * Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX * In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX * Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope * Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%) * Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%) * Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%) * Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%) * The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women * It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion * Vaccination with SHINGRIX may not result in protection of all vaccine recipients References: 1. Prescribing Information for SHINGRIX. 2. Berlinberg EJ, Kim E, Deiner MS, Patterson C, Porco TC, Acharya NR. Sesonality of herpes zoster and herpes zoster ophthalmicus. J Clin Virol. 2020;126:104306. 3. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103-108. * Educational Event Schedules * EHR Resources * CDC Supply Information * Vaccine Info Statement * Medical Inquiries Questions About SHINGRIX? Call: 1-800-772-9292 Available Monday - Friday 8:30 am to 5:30 pm ET You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967. * Legal Notice * Privacy Notice * Interest-based Ads * Contact Us * Unsubscribe Your Privacy Choices Trademarks are owned by or licensed to the GSK group of companies. This website is funded and developed by GSK. This site is intended for US healthcare professionals only. ©2022 GSK or licensor. SGXWCNT230027 May 2023 Produced in USA. Expand/Collapse Indication & Important Safety Info Indication SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles): * in adults aged 50 years and older. * in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox). SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles): * in adults aged 50 years and older. * in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox). Important Safety Information * SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX * Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX * SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX * Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX Chat with GSKBack to Top This site uses cookies and similar technologies (collectively, "cookies") to enhance your website experience and track the site's performance. These cookies are automatically enabled. By using this site, you agree to our use of these cookies in accordance with our Privacy Notice. Click on Privacy Choices below to manage your preferences, including to opt out of the sale or sharing of your information. Privacy Choices Managing Privacy Options OPT OUT OF SALE AND SHARING OF INFORMATION Your state law may allow you the right to opt out of the sale or sharing of your personal information for targeted advertising. You may opt out of such sale or share via the toggle available to you for "Targeting Cookies," and selecting the "Confirm my choices” button below. To limit sale or sharing of your information for targeting advertising offline, please see the "Cookies and Targeted Advertising Choices," section in the Privacy Notice and submit the required form. Strictly Necessary Cookies Always Active Necessary for the website to function appropriately, such as to store session data during a website visit, to manage cookie and tag preferences, and to protect the security of the website. In addition, some of these cookies are set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. Performance Cookies Always Active Enable the website to provide enhanced functionality and personalization, such as by helping us to measure how many visitors come to our websites, what sites our website visitors come from, and how often certain pages on our website are viewed. These cookies may be set by us or by third party providers, like our analytics service providers, whose services we have added to our pages. Targeting Cookies Allow us to target and re-target you with relevant advertising. We and our advertising partners use information collected through these technologies to infer your interests in order to serve you more relevant advertisements on other sites. If you don’t allow these cookies, you will receive advertising, but it may be less relevant to you. Confirm my choices